Revenues for the third quarter of 2009 were $11.62 billion, down 3%, compared to $11.97 billion for the third quarter of 2008.

For the first nine months ended September 30, 2009, the company has reported a net income of $7.87 billion, or $1.16 per diluted share, compared to $7.84 billion, or $1.16 per diluted share, for the first nine months ended September 30, 2008.

For the first nine months of 2009, revenues were $33.5 billion, a decrease of 7%, compared with $36 billion in the same period of 2008.

Jeff Kindler, chairman and CEO of Pfizer, said: "We are pleased with our results this quarter and in our ability to once again deliver solid operational performance in an environment that continues to be challenging. Excluding foreign exchange, our five pharmaceutical units and animal health business continued to perform well enabling us to continue to meet our commitments."

A service of YellowBrix, Inc.